RS58324B1 - Nova kondenzovana imidazobenzotiazolska jedinjenja - Google Patents

Nova kondenzovana imidazobenzotiazolska jedinjenja

Info

Publication number
RS58324B1
RS58324B1 RS20190084A RSP20190084A RS58324B1 RS 58324 B1 RS58324 B1 RS 58324B1 RS 20190084 A RS20190084 A RS 20190084A RS P20190084 A RSP20190084 A RS P20190084A RS 58324 B1 RS58324 B1 RS 58324B1
Authority
RS
Serbia
Prior art keywords
imidazo
alkyl
tert
butyl
pyrazol
Prior art date
Application number
RS20190084A
Other languages
English (en)
Serbian (sr)
Inventor
Pundlik Shinde
Sanjay Srivastava
Davindar Tuli
Deepak Rai
Prashant Gj
Shailesh Deshpande
Rameshchandra Gupta
Vijay Chauthaiwale
Chaitanya Dutt
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of RS58324B1 publication Critical patent/RS58324B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
RS20190084A 2014-03-27 2015-03-24 Nova kondenzovana imidazobenzotiazolska jedinjenja RS58324B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1089MU2014 2014-03-27
PCT/IB2015/052124 WO2015145336A1 (en) 2014-03-27 2015-03-24 Novel fused imidazobenzothiazole compounds
EP15717242.0A EP3122755B1 (en) 2014-03-27 2015-03-24 Novel fused imidazobenzothiazole compounds

Publications (1)

Publication Number Publication Date
RS58324B1 true RS58324B1 (sr) 2019-03-29

Family

ID=54194050

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190084A RS58324B1 (sr) 2014-03-27 2015-03-24 Nova kondenzovana imidazobenzotiazolska jedinjenja

Country Status (30)

Country Link
US (2) US9908898B2 (enExample)
EP (1) EP3122755B1 (enExample)
JP (1) JP6480949B2 (enExample)
KR (1) KR102339610B1 (enExample)
CN (1) CN106414458B (enExample)
AR (1) AR099867A1 (enExample)
AU (1) AU2015237840B2 (enExample)
CA (1) CA2943098C (enExample)
CY (1) CY1121147T1 (enExample)
DK (1) DK3122755T3 (enExample)
EA (1) EA029745B9 (enExample)
ES (1) ES2707099T3 (enExample)
HR (1) HRP20190121T1 (enExample)
HU (1) HUE042493T2 (enExample)
IL (1) IL247955B (enExample)
LT (1) LT3122755T (enExample)
MX (1) MX368985B (enExample)
MY (1) MY193041A (enExample)
PH (1) PH12016501903B1 (enExample)
PL (1) PL3122755T3 (enExample)
PT (1) PT3122755T (enExample)
RS (1) RS58324B1 (enExample)
SG (1) SG11201607793RA (enExample)
SI (1) SI3122755T1 (enExample)
SM (1) SMT201900036T1 (enExample)
TR (1) TR201900735T4 (enExample)
TW (1) TWI648282B (enExample)
UA (1) UA121469C2 (enExample)
WO (1) WO2015145336A1 (enExample)
ZA (1) ZA201606598B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物
DE102016209204A1 (de) 2016-05-27 2017-11-30 Robert Bosch Gmbh Vorrichtung zur Regelung mindestens eines Fluidstroms in einem Fahrzeug
KR102630959B1 (ko) * 2016-10-31 2024-01-29 엘지디스플레이 주식회사 유기 화합물과 이를 이용한 발광다이오드 및 유기발광다이오드 표시장치
CN106727538A (zh) * 2017-02-20 2017-05-31 潘连香 一种治疗2型糖尿病的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724566D0 (en) 1987-10-20 1987-11-25 Roussel Lab Ltd Chemical compounds
GB8908845D0 (en) 1989-04-19 1989-06-07 Roussel Lab Ltd Chemical compounds
WO1995029922A1 (en) * 1994-04-29 1995-11-09 Pharmacia & Upjohn Company Methanol derivatives for treatment of retroviral infections especially hiv infections
WO2002014321A1 (en) 2000-08-11 2002-02-21 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
CA2506796A1 (en) * 2002-11-25 2004-06-10 Pharmacia Corporation Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
JP2009526037A (ja) * 2006-02-09 2009-07-16 ファイザー・リミテッド トリアゾロピリジン化合物
TWI648282B (zh) * 2014-03-27 2019-01-21 印度商托仁特生技有限公司 新熔合咪唑苯并噻唑化合物

Also Published As

Publication number Publication date
JP6480949B2 (ja) 2019-03-13
US20180127437A1 (en) 2018-05-10
MY193041A (en) 2022-09-23
AR099867A1 (es) 2016-08-24
US10227361B2 (en) 2019-03-12
ES2707099T3 (es) 2019-04-02
EP3122755B1 (en) 2018-11-07
TR201900735T4 (tr) 2019-02-21
IL247955A0 (en) 2016-11-30
PH12016501903A1 (en) 2017-01-09
UA121469C2 (uk) 2020-06-10
SMT201900036T1 (it) 2019-02-28
MX2016012535A (es) 2017-05-04
SI3122755T1 (sl) 2019-02-28
CN106414458A (zh) 2017-02-15
WO2015145336A1 (en) 2015-10-01
KR102339610B1 (ko) 2021-12-14
EA029745B9 (ru) 2018-08-31
TW201613941A (en) 2016-04-16
CY1121147T1 (el) 2020-05-29
CA2943098A1 (en) 2015-10-01
ZA201606598B (en) 2017-11-29
NZ724342A (en) 2021-02-26
EP3122755A1 (en) 2017-02-01
MX368985B (es) 2019-10-23
EA029745B1 (ru) 2018-05-31
PL3122755T3 (pl) 2019-05-31
TWI648282B (zh) 2019-01-21
CA2943098C (en) 2022-07-05
AU2015237840B2 (en) 2019-06-20
PH12016501903B1 (en) 2019-04-26
EA201691920A1 (ru) 2017-01-30
IL247955B (en) 2021-02-28
US9908898B2 (en) 2018-03-06
CN106414458B (zh) 2019-10-29
AU2015237840A1 (en) 2016-09-29
US20170107233A1 (en) 2017-04-20
HUE042493T2 (hu) 2019-07-29
KR20160129089A (ko) 2016-11-08
HRP20190121T1 (hr) 2019-03-08
LT3122755T (lt) 2019-02-11
SG11201607793RA (en) 2016-10-28
JP2017513825A (ja) 2017-06-01
DK3122755T3 (en) 2019-02-18
PT3122755T (pt) 2019-01-30

Similar Documents

Publication Publication Date Title
US10227361B2 (en) Fused imidazobenzothiazole compounds
ES2983686T3 (es) Pirrolopirimidinas como potenciadores de CFTR
JP7609790B2 (ja) イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用
JP2021505684A (ja) ヒストンデアセチラーゼ６阻害剤としての１，２，４−オキサジアゾール誘導体
US20190127381A1 (en) Substituted fused pyrimidinone compounds
ES2731429T3 (es) Compuestos de indanilurea inhibidores de MAP quinasa P38
MX2012013438A (es) Inhibidores de cinasa del extremo n-terminal de c-jun (jnk).
NZ724342B2 (en) Novel fused imidazobenzothiazole compounds
WO2024161371A1 (en) Substituted azoles their use in the treatment of diseases associated with alpha-1 -antitrypsin (a1at) deficiency
HK1177931A1 (en) 2 -amino- pyrimidine derivatives useful as inhibitors of jnk